New York – October 19, 2026 -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) will report its third-quarter 2026 financial results on Tuesday, November 3, 2026, before the market opens. The expedition cruise and adventure travel operator will discuss the figures on an audio conference webcast the same morning.

Toronto – October 19, 2026 -- Vector Science and Therapeutics Corp. (TSXV: PAIN) has appointed Angus Jackson, a former investment banker at Outcome Capital, as Managing Director of Corporate Development. He will lead the company's inorganic growth initiatives, including acquisitions, investments and strategic partnerships.

Boston – October 19, 2026 -- Servier has dosed the first patients in EMBLEM-1, the pivotal Phase 2 cohort of its Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in aggressive adenoid cystic carcinoma (ACC), a cancer with no FDA-approved systemic treatment.

Emi-Le is an investigational antibody drug conjugate (ADC) directed against B7-H4. The cohort is enrolling under trial identifier NCT05377996.

Beverly, Mass. – October 19, 2026 -- DataOne Software, a Dominion Enterprises company, has added Massachusetts vehicle registration and sales data to its Cross-Sell Reports dealer market intelligence products, bringing coverage to 40 states.

Cross-Sell Reports process 3.8 million monthly transactions from state DMV records

The platform handles an average of more than 3.8 million new and used dealer transactions each month, all sourced from official state DMV records. Each dealer subscription is configured to the dealer's own market area.

New York – October 19, 2026 -- Global MedTech M&A value rose 160% in the first half of 2026 versus the same period of 2025, with total disclosed deal value reaching roughly US$130 billion, the highest level in more than a decade, according to the 20th edition of EY US's Pulse of the MedTech Industry report.

The recovery is narrow. EY found it was driven by a limited number of blockbuster transactions rather than broad-based dealmaking.

Secaucus – October 19, 2026 -- A broader set of lab criteria identified primary aldosteronism (PA) in 26.2% of 60,449 U.S. patients, twice the 13.0% flagged under the Endocrine Society's 2025 guidelines, according to a Quest Diagnostics (NYSE: DGX) study published in the journal Hypertension.

Las Vegas – October 19, 2026 -- Nicholas Air Founder and CEO Nicholas Correnti will address OEM part supply disruptions, engine OEM program shortfalls and regulatory bottlenecks in a fireside chat at the 2026 NBAA-BACE on Tuesday, October 20, at 2:15 PM on the Horizon Stage.

The convention runs October 19-22 in Las Vegas, Nevada. The National Business Aviation Association describes it as the largest annual gathering of the business aviation community, drawing flight department leaders and operational experts from around the world.

Chicago – October 19, 2026 -- The HNTB-designed South Conveyance Storm Sewer Project at O'Hare International Airport has won the American Society of Civil Engineers Illinois Section's 2026 Outstanding Civil Engineering Achievement Award in the more than $100 million category, after crews tunneled beneath active runways and taxiways without interrupting airport operations.

Bridgewater – – October 19, 2026 -- Insmed (Nasdaq: INSM) has launched BRINSUPRI Tablets 25 mg (brensocatib hydrate) in Japan, making it the first and only approved, commercially available treatment for non-cystic fibrosis bronchiectasis (NCFB) in the country.

Japan's health ministry cleared the once-daily oral tablet in August 2026

The Ministry of Health, Labour, and Welfare approved BRINSUPRI based on results from the Phase 3 ASPEN study. The label covers adults and pediatric patients aged 12 years and older.

San Diego – October 19, 2026 -- The U.S. Food and Drug Administration has cleared Protego Biopharma's Investigational New Drug application for PROT-001, allowing the company to start SHIELD-AL, a global pivotal Phase 2/3 study in newly diagnosed light chain (AL) amyloidosis patients.

PROT-001 is an oral, investigational, first-in-class lambda light chain stabilizer. Protego will test it as an add-on to standard-of-care plasma cell-directed therapy, which reduces light chain production.